NL-OMON51321招募中不适用
Percutaneous intratumoural holmium microspheres brachytherapy for patients with pancreatic cancer; a single centre, prospective safety and feasibility study - SLOTH-2a
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •1. Female or male aged 18 years and over.
- •2. Pathologically proven pancreatic adenocarcinoma, also known as pancreatic
- •ductal adenocarcinoma.
- •3. Patient is deemed ineligible for surgical resection of the pancreatic cancer:
- •a. in accordance with consensus at the multidisciplinary meetings/discussions,
- •b. and/or the patient refuses to undergo surgical resection out of personal
- •4. Life expectancy of 16 weeks or longer.
- •5. World Health Organisation (WHO) Performance status 0-1
- •6. One or more measurable pancreatic tumours of at least 20 mm in the longest
- •diameter by spiral CT or MRI according to the Response Evaluation Criteria in
- •Solid Tumours (RECIST) 1.1 criteria.
- •7. Negative pregnancy test for women of childbearing potential.
排除标准
- •1. Radiation therapy within the last 4 weeks before the start of study therapy.
- •2. Chemotherapy within the last 2 weeks before the start of study therapy.
- •3. Calcifications in the pancreas or tumour that are highly expected to
- •obstruct the needle tract
- •4. Any unresolved toxicity >= grade 3 from the National Cancer Institute (NCI),
- •Common Terminology Criteria for Adverse Events (CTCAE version 5.0) from
- •previous anti-cancer therapy.
- •5. Leukocytes < 3.0 109/l and/or platelet count < 75 109/l.
- •6. Kidney failure: Creatine > 165 µmol/l and/or eGFR < 60 ml/min/1,73m2
- •7. Significant cardiac event classification of heart disease >=2 within 3 months
- •before entry, or presence of cardiac disease that in the opinion of the
- •Investigator increases the risk of ventricular arrhythmia.
- •8. Patient is deemed ineligible for implantation of 166Ho by an expert panel
- •(surgeon, nuclear medicine physician, interventional radiologist, radiologist,
- •and researcher) due to tumour anatomy, nearby structures, patient status or a
- •combination.
- •9. Pregnancy or breast feeding (women of child-bearing potential).
- •10. Patients suffering from psychic disorders that make a comprehensive
- •judgement impossible, such as psychosis, hallucinations and/or depression.
- •11. Patients who are declared incompetent.
研究者
相似试验
已完成
不适用
Intratumoral holmium microspheres brachytherapy for patients with pancreatic cancer; a single center, non-randomized, feasibility study in an open surgical setting- the SLOTH1 studyPancreatic cancerNL-OMON49772Radboud Universitair Medisch Centrum6
进行中(未招募)
不适用
Percutaneous Holmium Injection in Pancreatic CancerPancreas CancerNCT05880472Radboud University Medical Center6
已完成
2 期
Radioactive holmium microspheres for the treatment of patients with unresectable liver metastases; a single center, interventional, non-randomized, phase II efficacy (HEPAR II) trial.NL-OMON39704niversitair Medisch Centrum Utrecht48
已完成
不适用
Radioactive holmium microspheres for the treatment of patients with non-resectable liver metastases of mixed origin; a single center, interventional, non-randomized, open label, safety study.liver metastases of mixed origines10019815NL-OMON35649niversitair Medisch Centrum Utrecht24
已完成
不适用
Radioembolization with holmium-containing microspheres: Use of the Holmium Platform for the treatment of patients with hepatocellular carcinomaC22.0Liver cell carcinomaDRKS00032073niversitätsklinikum Jena, Klinik für Nuklearmedizin27
